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Haematopoiesis is a highly organized and complex developmental process where the hematopoietic stem cells lie at the apex of hierarchy and differentiate into all types of lineage-committed progenitors and mature blood cells. Identifying the distinct lineage-primed progenitors and gaining insights into the lineage commitment events are important for dissecting the developmental pathways of normal haematopoiesis and for understanding the underlying mechanisms in leukemogenesis.
In the adult human bone marrow (BM), megakaryocyteerythrocyte progenitors (MEPs) have been identified in the committed progenitor enriched lineage-marker negative (Lin−) CD34+CD38+ compartment as CD123−CD45RA−, while common myeloid progenitors and granulocyte-macrophage progenitors have been defined as CD123 lo CD45RA− and CD123 lo CD45RA+, respectively. 1 that the more primitive stem cell-enriched BM Lin−CD34+CD38− fraction also contains progenitors of varying maturation and differentiation potentials, including MEPs. 2 So far, the markers to identify this distinct MEP population in the Lin−CD34+CD38− fraction have not been identified.
Here we show that the CD34+CD38− integrin α2− cell fraction of adult human BM contains in a high frequency hematopoietic progenitors with erythroid (burst-forming unit-erythroid (BFU-E)) as well as megakaryocytic (colony-forming unit-megakaryocyte (CFU-MK)) commitment analyzed in methylcellulose and collagen cultures, respectively. By using a single-cell serum-free liquid culture assay, we show that the Lin−CD34+CD38− integrin α2− cell fraction, further defined as CD45RA−, contains, in addition to unilineage-committed erythroid and megakaryocytic progenitors, in a high frequency MEP cells with bipotential differentiation capacity towards both lineages, enabling further studies on the molecular pathways regulating early erythroid-megakaryocytic commitment.
BM aspirates from healthy adult volunteers were collected with informed consent in accordance with institutional guidelines and approved by the local research ethics committee. Detailed information about the methods, including cell isolation, the antibodies used, colony assays and single-cell serum-free liquid cultures and gene expression analysis are described in Supplementary Information.
By fluorescence-activated cell sorting (FACS), integrin α2 was found to be expressed in most BM CD34+CD38− cells (96.7 ± 3.2%; mean ± s.d., n = 25; Supplementary Figure S1a) , in contrast to a much more restricted expression in cord blood CD34−CD38− cells. 3 The CD34+CD38− integrin α2+ and integrin α2− cells were sorted by FACS for testing their colony-forming capacity (Figure 1a ). The longterm culture-initiating cell assay, which measures hematopoietic stem cell activity but not committed progenitors, showed that long-term culture-initiating cells resided exclusively in the CD34 +CD38− integrin α2+ fraction (Supplementary Figure S1b) . The granulocyte-macrophage progenitors (CFU-GM) were significantly enriched in the integrin α2+ fraction (Figure 1b) . Notably, the erythroid BFU-E and megakaryocyte CFU-MK progenitors were found in a significantly higher frequency in the CD34+CD38− integrin α2− than in the integrin α2+ fraction (Figure 1c ). In agreement with these findings, single-cell colony assays showed that 22% of the single Lin−CD34+CD38− integrin α2− cells formed BFU-E, in contrast to o1% of the corresponding integrin α2+ fraction (Figure 1d ). The CD45RA+ fraction within the Lin−CD34 +CD38− integrin α2− cells had a very low myeloid clonogenic potential (data not shown), in line with a previous report, 4 and was excluded from further assays. The integrin α2+ and integrin α2− expressing cells within the Lin−CD34+CD38− compartment are not well demarcated, and therefore the minor CFU-GM population in the CD34+CD38− integrin α2− fraction in the methylcellulose cultures may represent contamination of the integrin α2+ cells.
CD33, a pan-myeloid marker, is expressed in granulocytemacrophage progenitors and common myeloid progenitors but not in MEPs within the BM CD34+CD38+ cells. 5 Accordingly, the Lin−CD34+CD38−CD45RA− integrin α2− cell population was uniformly CD33− (Figure 1e ). Within the Lin−CD34+CD38+ progenitor cell fraction, MEPs (CD123−CD45RA−) are predominantly CD135−, whereas most common myeloid progenitor (CD123 lo CD45RA−) are CD135+. 6, 7 In agreement with this, our data show that most Lin−CD34+CD38−CD45RA− integrin α2− cells do not express CD135 (Figure 1e ), providing additional evidence for the downregulation of CD135 during early erythroid and megakaryocytic differentiation.
The existence of bipotent MEPs in the Lin−CD34+CD38−CD45RA− integrin α2− cell fraction was studied by a single-cell liquid culture assay using serum-free culture conditions 2 (Figure 2) . At days 12-14 of culture, 30-40% of the wells contained clones, with 1/3 of the clones covering 50-100% of the well surface area in Terasaki plates (Supplementary Figure S2b) . Importantly, in FACS analysis of 32 clones derived from single Lin−CD34+CD38−CD45RA− integrin α2− cells, all clones contained CD41−CD235+ erythroid cells, whereas 22/32 of the clones contained both erythroid and megakaryocytic CD41+CD235− cells, confirming bilineage potential of these cells (Figures 2a and c) . As shown previously, 2 the frequency of megakaryocytic cells was much lower than that of erythroid cells in the clones with bilineage differentiation (Figure 2b ). During megakaryocytic differentiation, the cells acquired integrin α2 expression, 8 while the erythroid cells remained integrin α2− (Figure 2a ).
For morphological analysis, 83 single-cell-derived clones were individually transferred to cytospin slides and stained by May-Grünwald-Giemsa (Figures 2d and e ). This also allowed an evaluation of the clones with very low cell numbers, which could not be analyzed by FACS. These small clones invariably consisted of megakaryocytic cells (Figure 2e ). Apart from these small megakaryocytic clones, bipotential MEP clones were identified by morphology in a similar proportion as by FACS analysis (Figure 2c ). Taken together, our data demonstrate a high frequency of bipotential MEPs in adult BM Lin−CD34+CD38 −CD45RA− integrin α2− cell fraction.
The cytokine combination used in the single-cell serum-free liquid cultures has been previously shown to support growth of myeloid progenitors. 2 In agreement with this, the clones derived from the single adult BM Lin−CD34+CD38−CD45RA− integrin α2+ cells cultured in the same serum-free liquid culture conditions generated 0.2-56% of myeloid cells (Supplementary Figure S3) . In contrast, a low frequency of myeloid cells (0.13, 0.2 and 0.41% of cells) was seen in only 3 of the 32 Lin−CD34+CD38−CD45RA− integrin α2− single-cell-derived clones (data not shown), further supporting the notion that most of the cells are bipotent MEPs or their downstream progenitors.
Furthermore, our gene expression analysis provides molecular evidence for enrichment of erythroid and megakaryocytic-primed progenitors in the Lin−CD34+CD38− integrin α2− cells. Increased expression of hemoglobin delta was detected in integrin α2− cells ( Supplementary Figure S4a , Supplementary  Table S1 ). Notably, quantitative PCR analysis showed upregulation of the key regulator GATA-2, which is highly expressed in early erythroid cells and megakaryocytes, 9 and downregulation of hematopoietic stem cell regulator GATA-3 10,11 in the integrin α2− cell fraction (Supplementary Figure S4b) , providing evidence that most integrin α2− cells are transcriptionally primed towards erythroid and megakaryocytic lineages
In conclusion, here we have identified a novel bipotential MEP cell population in Lin−CD34+CD38−CD45RA− integrin α2− cells in adult human BM. The identification of this novel MEP population provides a means for further analysis of the regulation of erythroid and megakaryocytic lineage fate decisions under physiological condition and for study of cellular mechanisms for myeloid leukemia. In addition, this finding may facilitate studies aiming to expand these lineages for clinical transfusion therapy. Rearrangements of the platelet-derived growth factor receptor genes (PDGFRA/B) are associated with imatinib-responsive myeloproliferative neoplasms (MPN). Together with diseases involving rearrangements of the fibroblast growth factor receptor gene FGFR1, these molecularly defined entities are grouped together by the World Health Organisation as myeloid/lymphoid neoplasms with rearrangements of PDGFRA, PDGFRB or FGFR1. Tyrosine kinase inhibitor treatment can radically alter the course of these diseases, and prompt diagnosis is important. FIP1L1-PDGFRA is the commonest rearrangement involving PDGFRA. It poses a diagnostic challenge as it is cytogenetically cryptic in most instances, involving a small interstitial deletion on chromosome 4. 1 Diagnosis of this disease requires specific testing by fluorescence in situ hybridization (FISH) for the CHIC2 deletion or PCR to detect the FIP1L1-PDGFRA fusion gene. Conversely, more than 20 translocation partners of PDGFRB are known to cause MPN, often with a clinical presentation of chronic eosinophilic leukemia (CEL). All previously reported PDGFRB fusion genes in CEL/MPN have been associated with translocations involving chromosome 5, and evident on metaphase cytogenetics. 2 Nevertheless, there have been cases of imatinib-responsive CEL/MPN without an identified rearrangement of PDGFRA/B. We report an unusual case of CEL/MPN due to a cytogenetically cryptic deletion involving PDGFRB.
In 2011 a 70-year-old man was assessed after 5 years of asymptomatic leukocytosis and thrombocytosis. The bone marrow biopsy (BMBx; Figure 1a ) showed granulocytic proliferation with no dysplasia and no fibrosis. Mast cells were mildly increased with no focal clusters. The absolute eosinophil count was mildly elevated (1.6x10 9 /l; 6% of leukocytes). JAK2 V617F was not detected and the karyotype was normal with good resolution (400 bands per haploid set). Hydroxyurea treatment was commenced for 'unclassified MPN'. Over the following years there was slowly progressive anemia eventually resulting in red cell transfusion dependency. In 2014 he developed marked eosinophilia (17.9 × 10 9 /l; 32% of leukocytes). The follow-up BMBx showed eosinophilia and an increase in immature precursors (Figure 1b) . A new karyotypic abnormality, der(3)(pter-4p23::p21-4p23::p14-4qter), was detected in 35/36 metaphases. This abnormality is not known to have a specific disease association. The serum tryptase level was elevated (42 μg/l; normal o12), and is often a feature of myeloid neoplasms with rearrangements of PGDFRA/B. 3 In response to the emergence of marked eosinophilia, genetic assessment for cryptic rearrangements of PDGFRA/B and FGFR1 was initiated. PDGFRB FISH showed loss of the 5′ signal, and single-nucleotide polymorphism (SNP) array confirmed an interstitial deletion of~870 kb of chromosome 5q involving telomeric PDGFRB and extending into the tumor necrosis factor-α-induced protein 3-interacting protein 1 (TNIP1) gene. RNA sequencing was performed and read pairs were mapped to the human genome. 4 Visual inspection of the reads mapping to PDGFRB revealed expression of chimeric TNIP1-PDGFRB mRNA (Figure 2a ). The function of TNIP1 is poorly understood, but it may have a role in predisposition to autoimmune disorders. 5 TNIP1 contains several coiled coil domains, which may contribute to oligomerization and activation of other known fusion oncoproteins. TNIP1 is more highly expressed in hematopoietic cells than is PDGFRB (www. genecards.org; accessed 13 Feb 2015) and TNIP1-PDGFRB was over-expressed relative to normal PDGFRB transcripts (data not shown). The fusion gene was confirmed using PCR with reverse transcription (RT-PCR) with primers located in exon 15 of TNIP1 and exon 11 of PDGFRB (Figure 2b) . The in-frame transcripts fused exon 17 of TNIP1 to exon 11 of PDGFRB. In common with the great majority of reported PDGFRβ oncoproteins the predicted TNIP1-PDGFRβ protein retains both the transmembrane domain (exon 11) and the catalytic domain (exons 13-21) of PDGFRβ. The transmembrane domain has been shown to have a critical role in PDGFRβ-driven myeloid proliferation. 6 Retrospective FISH analysis of an archived sample from 2011 confirmed that the TNIP1-PDGFRB rearrangement was present in 490% of interphase cells before the emergence of marked eosinophilia. Clonal evolution and hematological acceleration had occurred in the interim, a pattern resembling the accelerated phase Accepted article preview online 27 October 2015; advance online publication, 27 November 2015
